THE APHERESIS- DATABASE (APHDA)-PROJECT- PATIENT CHARACTERISTICS & TREATMENT PATTERNS OF APHERESIS PATIENTS IN GERMANY
Author(s)
Schmid T, Michailov G
Amgen GmbH, Munich, Germany
OBJECTIVES: According to the German healthcare system patients with homozygous familial hypercholesterolemia or severe hypercholesterolemia are eligible for apheresis, if LDL-C-target-levels cannot be reached with maximized lipid-lowering therapy (documented over 12 months). Apheresis is an invasive and costly therapy, and thus seen as the “ultima ratio treatment” for hypercholesterolemia patients. The APHDA-project aimed to assess patient characteristics and treatment patterns of apheresis patients in Germany. METHODS: Inclusion criteria for this project were diagnosis of hypercholesterolemia, granted approval and currently ongoing apheresis treatment.Information has been extracted from medical charts. RESULTS: CONCLUSIONS: This study represents >20% of patients currently on apheresis in Germany (N=1350). Majority (56.76%) of patients were >60 years with 8 patients <40 years indicative for a genetic disposition. For the 16.55% on apheresis for >10 years this therapy seems well established in their daily-life; however, 21.62% more recently initiated apheresis-treatment (<3 years). LDL-C-levels were relatively high, with 84.46% in need of additional lipid-lowering therapies to reach recommended LDL-target (<100 or <70mg/dl). On average, patients were on apheresis for 6 years starting with a mean LDL of 260mg/dl suggesting high residual CV-risk, and highlighting the needs for convenient and effective alternative treatment options.
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PCV154
Topic
Health Service Delivery & Process of Care
Topic Subcategory
Treatment Patterns and Guidelines
Disease
Cardiovascular Disorders